Metformin is a drug that affects the digestive system and metabolism. It is an antidiabetic drug.
Indications for use
Type 2 diabetes mellitus with ineffective diet therapy and exercise regimen, especially in patients with excess body weight:
as monotherapy or as part of combination therapy in combination with other oral hypoglycemic agents or in combination with insulin for the treatment of adults; as monotherapy or as part of combination therapy with insulin for the treatment of children aged 10 years and older and adolescents.
To reduce the complications of diabetes in adult patients with type 2 diabetes and overweight as a first-line drug after ineffective diet therapy.
Warehouse
1 tablet contains metformin hydrochloride in terms of 100% substance 850 mg; excipients: sodium starch glycolate (type A), povidone, corn starch, magnesium stearate, colloidal anhydrous silicon dioxide; film coating composition: hypromellose, polyethylene glycol 6000, talc, titanium dioxide (E171), propylene glycol.
Contraindication
Hypersensitivity to metformin or to any of the excipients; any type of acute metabolic acidosis (e.g. lactic acidosis, diabetic ketoacidosis); diabetic precoma; severe renal insufficiency (glomerular filtration rate (GFR) < 30 ml/min);
Method of application
The usual starting dose is 500 mg or 850 mg (Metformin, film-coated tablets, 500 mg or 850 mg) 2–3 times daily with or after meals.
After 10–15 days, the dose should be adjusted according to the results of serum glucose measurements.
Slowly increasing the dose helps reduce side effects from the digestive tract.
Application features
Patients should follow a diet with a uniform intake of carbohydrates throughout the day. Overweight patients should continue to follow a low-calorie diet. Patients' carbohydrate metabolism should be monitored regularly.
Pregnant women
Preclinical studies have not revealed any adverse effects on pregnancy, embryonic or fetal development, childbirth, or postnatal development.
Children
The drug Metformin should be used in children over 10 years of age and adolescents.
Drivers
Metformin monotherapy does not affect the reaction speed when driving or using other mechanisms, since the drug does not cause hypoglycemia. However, caution should be exercised when using metformin in combination with other hypoglycemic agents (sulfonylureas, insulin or meglitinides) due to the risk of hypoglycemia.
Overdose
When using the drug in a dose of 85 g, hypoglycemia was not observed. However, in this case, the development of lactic acidosis was observed. A significant excess of the metformin dose or concomitant risk factors may cause the occurrence of lactic acidosis.
Side effects
Metabolic disorders: lactic acidosis
From the nervous system: taste disturbance.
Hepatobiliary disorders: abnormal liver function tests or hepatitis, which completely disappear after metformin withdrawal.
Skin and subcutaneous tissue disorders: skin reactions including erythema, pruritus, urticaria.
Storage conditions
Store in original packaging at a temperature not exceeding 25°C. Keep out of the reach of children.
